{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(10)"],"submitter":["Geißler AL"],"pubmed_abstract":["EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylati"],"journal":["Oncotarget"],"pagination":["17164-17190"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5370031"],"repository":["biostudies-literature"],"pubmed_title":["ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer."],"pmcid":["PMC5370031"],"pubmed_authors":["Geißler AL","Fichter CD","Weddeling B","Makowiec F","Werner M","Lassmann S","Geißler M","Kottmann D","Lutz L","Fritsch R"],"additional_accession":[]},"is_claimable":false,"name":"ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.","description":"EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylati","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Mar","modification":"2026-05-30T13:07:18.325Z","creation":"2019-03-27T02:39:47Z"},"accession":"S-EPMC5370031","cross_references":{"pubmed":["28199979"],"doi":["10.18632/oncotarget.15211"]}}